Evidence map›Paper›PMID 28336715›Full record

ArticleMolecular & cellular proteomics : MCP2017

Monitoring Cell-surface

Mathias Kalxdorf, Stephan Gade, H Christian Eberl, Marcus Bantscheff

Open access · hybridAbstract read
In one paragraph

Article in Molecular & cellular proteomics : MCP, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 51 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Mathias KalxdorfFrom ‡Cellzome, A GSK Company, Meyerhofstrasse 1, 69117 Heidelberg, Germany.
Stephan GadeFrom ‡Cellzome, A GSK Company, Meyerhofstrasse 1, 69117 Heidelberg, Germany.
H Christian EberlFrom ‡Cellzome, A GSK Company, Meyerhofstrasse 1, 69117 Heidelberg, Germany hans-christian.h.eberl@gsk.com marcus.x.bantscheff@gsk.com.
Marcus BantscheffFrom ‡Cellzome, A GSK Company, Meyerhofstrasse 1, 69117 Heidelberg, Germany hans-christian.h.eberl@gsk.com marcus.x.bantscheff@gsk.com.ORCID 0000-0002-8343-8977
European Molecular Biology Organization · DEGlaxoSmithKline (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The plasma membrane proteome plays a crucial role in inter- and intracellular signaling, cell survival, and cell identity. As such, it is a prominent target for pharmacological intervention. The relatively low abundance of this subproteome in conjunction with challenging extractability and solubility still hampers its comprehensive analysis. Here, we combined a chemical glycoprotein-tagging strategy with mass spectrometry to enable comprehensive analysis of the cell-surface glycoproteome. To benchmark this workflow and to provide guidance for cell line selection for functional experiments, we generated an inventory of the

Indexed as

Cell DifferentiationBiotinylationCell LineCell MembraneDasatinibGlycoproteinsHumansMacrophagesMembrane ProteinsMonocytesProtein Kinase InhibitorsProteomeProteomicsReproducibility of ResultsDasatinibGlycoproteinsMembrane ProteinsProtein Kinase InhibitorsProteome

Identifiers

PMID28336715
PMCPMC5417820
OpenAlexW2598935811

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.